Loading...
Loading...
Biogen
Idec
BIIB and Samsung
Bioepis today announced that through their joint venture, Biogen
Idec has exercised its right to enter into an agreement to commercialize
anti-TNF biosimilar product candidates in Europe, including biosimilars
for widely used therapies to treat conditions such as rheumatoid
arthritis and Crohn's disease.
Under the agreement, Biogen Idec will be responsible for
commercialization of these product candidates across Europe, where there
already exists a strong market for biosimilars and a defined regulatory
pathway. The agreement with Samsung Bioepis aligns with Biogen Idec's
broader corporate objectives of remaining focused on its core business,
while leveraging its expertise in manufacturing and specialty
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in